Abstract
Objective
A SARS-CoV-2 Omicron (BA.5.2) epidemic began in China in December, 2022 following stopping the zero COVID policy.
Methods
We studied features of the epidemic in 1,121 persons with chronic myeloid leukaemia (CML).
Results
1103 (98%) were in chronic, 10 in accelerated and 8 in acute phases. 834 (74%) became infected almost all of whom met criteria for COVID-19. The most common symptoms were fever (91%), cough (90%) and fatigue (82%). 42 infected persons were asymptomatic. Most people quarantined at home and self-medicated. 22 were hospitalized for COVID-19. At admission 5 had mild, 14, moderate and 3, severe/critical disease according to World Health Organization (WHO) criteria. 5 received respiratory assistance, 3 were admitted to the intensive care unit (ICU) and 1 in accelerated phase died from COVID-19. Co-variates associated with a risk of COVID-19 in SARS-CoV-2-infected subjects include age ≥ 65 years, higher education level and imatinib therapy.
Conclusion
In conclusion, most SARS-CoV-2 Omicron BA.5.2 infections in persons with CML resulted in COVID-19 most of which cases are mild with only 1 death.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data are included in the typescript. Inquiries should be directed to the corresponding authors.
References
Banerjee S, Yadav S, Banerjee S, Fakayode SO, Parvathareddy J, Reichard W et al (2021) Drug repurposing to identify nilotinib as a potential SARS-CoV-2 main protease inhibitor: insights from a computational and in vitro study. J Chem Inf Model 61(11):5469–5483. https://doi.org/10.1021/acs.jcim.1c00524
Başcı S, Ata N, Altuntaş F, Yiğenoğlu TN, Dal MS, Korkmaz S et al (2020) Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract 26(7):1676–1682. https://doi.org/10.1177/1078155220953198
Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M et al (2022) COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. Br J Haematol 196(3):559–565. https://doi.org/10.1111/bjh.17890
Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al (2014) Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58(8):4885–4893. https://doi.org/10.1128/aac.03036-14
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966–984. https://doi.org/10.1038/s41375-020-0776-2
Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY (2022) Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nat Med 28(9):1933–1943. https://doi.org/10.1038/s41591-022-01887-z
Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP et al (2020) COVID-19 in persons with chronic myeloid leukaemia. Leukemia 34(7):1799–1804. https://doi.org/10.1038/s41375-020-0853-6
Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A et al (2022) Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet 399(10335):1618–1624. https://doi.org/10.1016/s0140-6736(22)00327-0
Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F et al (2020) Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 7(10):e737–e745. https://doi.org/10.1016/s2352-3026(20)30251-9
Petersen E, Ntoumi F, Hui DS, Abubakar A, Kramer LD, Obiero C et al (2022) Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)—highlights Africa’s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis 114:268–272. https://doi.org/10.1016/j.ijid.2021.11.040
WHO (2022) WHO Guidelines Approved by the Guidelines Review Committee. Clinical Management of COVID-19 Living Guideline. World Health Organization
Acknowledgements
RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre and the Ministry of Science and Technology of China (84000-51200002).
Funding
This study is funded by National Institute of Health Research (NIHR) Biomedical Research Centre and the Ministry of Science and Technology of China (84000-51200002).
Author information
Authors and Affiliations
Contributions
M-WL, L-YZ, and QB-L designed the study and provided subjects. FC, HX, SY-C, JQ, and HG collected and analyzed the data. M-WL, L-YZ, RPG, SY-C, JQ, HG and FC prepared the typescript. All authors approved the final typescript, take responsibility, for the content and agreed to submit for publication.
Corresponding authors
Ethics declarations
Conflict of interest
RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd.
Ethics statement
The study was approved by the Institutional Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China) ([2023] 0065). The requirement for written informed consent was waived.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cheng, F., Xiang, H., Gale, R.P. et al. SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia. J Cancer Res Clin Oncol 149, 11025–11030 (2023). https://doi.org/10.1007/s00432-023-04995-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-04995-6